Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report published on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

CHEK stock opened at $0.89 on Tuesday. The stock has a market cap of $5.21 million, a price-to-earnings ratio of -0.30 and a beta of 0.19. The company has a 50 day simple moving average of $0.93 and a 200 day simple moving average of $1.11. Check-Cap has a 1 year low of $0.56 and a 1 year high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.